Nanoparticles for Oral Delivery: Design, Evaluation and State-of-the-art

Overview

Journal J Control Release

Specialty Pharmacology

Date 2016 Jun 14

PMID 27292178

Citations 113

Authors

Abhijit A Date

Justin Hanes

Laura M Ensign

Affiliations

Soon will be listed here.

Abstract

The oral route is a preferred method of drug administration, though achieving effective drug delivery and minimizing off-target side effects is often challenging. Formulation into nanoparticles can improve drug stability in the harsh gastrointestinal (GI) tract environment, providing opportunities for targeting specific sites in the GI tract, increasing drug solubility and bioavailability, and providing sustained release in the GI tract. However, the unique and diverse physiology throughout the GI tract, including wide variation in pH, mucus that varies in thickness and structure, numerous cell types, and various physiological functions are both a barrier to effective delivery and an opportunity for nanoparticle design. Here, nanoparticle design aspects to improve delivery to particular sites in the GI tract are discussed. We then review new methods for evaluating oral nanoparticle formulations, including a short commentary on data interpretation and translation. Finally, the state-of-the-art in preclinical targeted nanoparticle design is reviewed.

Citing Articles

Advances in Oral Biomacromolecule Therapies for Metabolic Diseases.

Jiao Q, Huang Y, He J, Xu Y Pharmaceutics. 2025; 17(2).

PMID: 40006605 PMC: 11859201. DOI: 10.3390/pharmaceutics17020238.

Chitosan Nanoparticle-Encapsulated Grown on Germinated Reduces Type II Alveolar Epithelial Cell Apoptosis in PM-Induced Lung Injury.

Kim H, Kim J, Park B, Park H Int J Mol Sci. 2025; 26(3).

PMID: 39940873 PMC: 11817496. DOI: 10.3390/ijms26031105.

Phytochemical-based nanosystems: recent advances and emerging application in antiviral photodynamic therapy.

Loo Y, Yusoh N, Lim W, Ng C, Zahid N, Azmi I Nanomedicine (Lond). 2025; 20(4):401-416.

PMID: 39848784 PMC: 11812329. DOI: 10.1080/17435889.2025.2452151.

Transforming Medicine: Cutting-Edge Applications of Nanoscale Materials in Drug Delivery.

Tenchov R, Hughes K, Ganesan M, Iyer K, Ralhan K, Lotti Diaz L ACS Nano. 2025; 19(4):4011-4038.

PMID: 39823199 PMC: 11803921. DOI: 10.1021/acsnano.4c09566.

Chinese herbal medicine-derived extracellular vesicles as novel biotherapeutic tools: present and future.

Zhang J, Tian S, Guo L, Zhao H, Mao Z, Miao M J Transl Med. 2024; 22(1):1059.

PMID: 39587576 PMC: 11587639. DOI: 10.1186/s12967-024-05892-3.

References

Reineke J, Cho D, Dingle Y, Morello 3rd A, Jacob J, Thanos C . Unique insights into the intestinal absorption, transit, and subsequent biodistribution of polymer-derived microspheres. Proc Natl Acad Sci U S A. 2013; 110(34):13803-8. PMC: 3752225. DOI: 10.1073/pnas.1305882110. View

Jubeh T, Barenholz Y, Rubinstein A . Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes. Pharm Res. 2004; 21(3):447-53. DOI: 10.1023/B:PHAM.0000019298.29561.cd. View

Devriendt B, De Geest B, Goddeeris B, Cox E . Crossing the barrier: Targeting epithelial receptors for enhanced oral vaccine delivery. J Control Release. 2012; 160(3):431-9. DOI: 10.1016/j.jconrel.2012.02.006. View

McCracken K, Cata E, Crawford C, Sinagoga K, Schumacher M, Rockich B . Modelling human development and disease in pluripotent stem-cell-derived gastric organoids. Nature. 2014; 516(7531):400-4. PMC: 4270898. DOI: 10.1038/nature13863. View

Pusztai A, Ewen S, Grant G, Peumans W, Van Damme E, Rubio L . Relationship between survival and binding of plant lectins during small intestinal passage and their effectiveness as growth factors. Digestion. 1990; 46 Suppl 2:308-16. DOI: 10.1159/000200402. View

Singh I, Swami R, Khan W, Sistla R . Lymphatic system: a prospective area for advanced targeting of particulate drug carriers. Expert Opin Drug Deliv. 2013; 11(2):211-29. DOI: 10.1517/17425247.2014.866088. View

SCHANKER L, TOCCO D, Brodie B, Hogben C . Absorption of drugs from the rat small intestine. J Pharmacol Exp Ther. 1958; 123(1):81-8. View

Tariq M, Alam M, Singh A, Iqbal Z, Panda A, Talegaonkar S . Biodegradable polymeric nanoparticles for oral delivery of epirubicin: In vitro, ex vivo, and in vivo investigations. Colloids Surf B Biointerfaces. 2015; 128:448-456. DOI: 10.1016/j.colsurfb.2015.02.043. View

Puglia C, Bonina F . Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Expert Opin Drug Deliv. 2012; 9(4):429-41. DOI: 10.1517/17425247.2012.666967. View

10.

Foulke-Abel J, In J, Kovbasnjuk O, Zachos N, Ettayebi K, Blutt S . Human enteroids as an ex-vivo model of host-pathogen interactions in the gastrointestinal tract. Exp Biol Med (Maywood). 2014; 239(9):1124-34. PMC: 4380516. DOI: 10.1177/1535370214529398. View

11.

Hua S, Marks E, Schneider J, Keely S . Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomedicine. 2015; 11(5):1117-32. DOI: 10.1016/j.nano.2015.02.018. View

12.

Jepson M, Clark M, Hirst B . M cell targeting by lectins: a strategy for mucosal vaccination and drug delivery. Adv Drug Deliv Rev. 2004; 56(4):511-25. DOI: 10.1016/j.addr.2003.10.018. View

13.

Erah P, Goddard A, Barrett D, Shaw P, Spiller R . The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother. 1997; 39(1):5-12. DOI: 10.1093/jac/39.1.5. View

14.

Vu L, Less R, Rajagopalan P . The promise of organotypic hepatic and gastrointestinal models. Trends Biotechnol. 2014; 32(8):406-13. DOI: 10.1016/j.tibtech.2014.04.006. View

15.

George M, Abraham T . Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan--a review. J Control Release. 2006; 114(1):1-14. DOI: 10.1016/j.jconrel.2006.04.017. View

16.

Braakhuis H, Kloet S, Kezic S, Kuper F, Park M, Bellmann S . Progress and future of in vitro models to study translocation of nanoparticles. Arch Toxicol. 2015; 89(9):1469-95. PMC: 4551544. DOI: 10.1007/s00204-015-1518-5. View

17.

Gamboa J, Leong K . In vitro and in vivo models for the study of oral delivery of nanoparticles. Adv Drug Deliv Rev. 2013; 65(6):800-10. PMC: 3773489. DOI: 10.1016/j.addr.2013.01.003. View

18.

Kim H, Ingber D . Gut-on-a-Chip microenvironment induces human intestinal cells to undergo villus differentiation. Integr Biol (Camb). 2013; 5(9):1130-40. DOI: 10.1039/c3ib40126j. View

19.

Sinha V, Kumria R . Microbially triggered drug delivery to the colon. Eur J Pharm Sci. 2003; 18(1):3-18. DOI: 10.1016/s0928-0987(02)00221-x. View

20.

Sedghi S, Fields J, KLAMUT M, Urban G, Durkin M, Winship D . Increased production of luminol enhanced chemiluminescence by the inflamed colonic mucosa in patients with ulcerative colitis. Gut. 1993; 34(9):1191-7. PMC: 1375452. DOI: 10.1136/gut.34.9.1191. View